Senile Dementia and Drug Therapy

  • Roland Branconnier
  • Jonathan O. Cole
Part of the Advances in Behavioral Biology book series (ABBI, volume 23)


As far as we can tell from the available literature, there are no specific drug therapies of major clinical benefit in senile dementia (Prien, 1973). Since the pathology of the condition has not been elucidated to the point of any specific remediable biochemical defect, specific therapy of the insulin — diabetes mellitus type has not been possible.


Cerebral Blood Flow Clinical Global Impression Ergot Alkaloid Senile Dementia Continuous Performance Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bouvier, J.B., Passeron, O. and Chapin, M.P. Psychometric study of praxilene. J. Int. Med. Res., 2:59–65, 1974.Google Scholar
  2. Cole, J. O., Branconnier, R.J. and Martin, G.F. Electroencephalogram and behavioral changes associated with papaverine administration in healthy geriatric subjects. J. Am. Geriatric Soc., 23:295–300, 1975.Google Scholar
  3. Eisdorfer, C., Conner, J.F. and Wilkie, F.L. Effects of magnesium pemoline on cognition and behavior. J. Gerontol., 23:283–288, 1968.PubMedGoogle Scholar
  4. Emmenegger, H. and Meier-Ruge, W. The action of hydergine and the brain, A histochemical, circulatory and neurophysiological study. Pharmacology, 1:65–78, 1968.PubMedCrossRefGoogle Scholar
  5. Ernst, A. M. Experiments with an o-methylated product of dopamine on cats. Acta Physiol. Pharmacol. Neerl., 11:48–53, 1962.PubMedGoogle Scholar
  6. Foley, J. M. Differential diagnosis of the organic mental disorders in the elderly patients. In: Aging and the Brain, (edited by Charles M. Gaitz), pp. 153–161, Plenum Press, New York, 1972.CrossRefGoogle Scholar
  7. Fontaine, L., Brand, M., Charbert, J., Szavasi, E. and Bayssat, M. Cerebral pharmacology of a new vasodilatory drug, Naftidrofuryl. Bull. Chem. Ther., 6:463–469, 1968.Google Scholar
  8. Grauer, H. and Kral, V.A. The use of imipramine (tofranil) in psychiatric patients of a geriatric outpatient clinic. Con. Medical Association J., 83:1423–1426, 1960.Google Scholar
  9. Hagberg, B. and Ingvar, D. H. Cognitive reduction in presenile dementia related to regional abnormalities of the cerebral blood flow. Br. J. Psychiatry, 128:209–222, 1976.PubMedCrossRefGoogle Scholar
  10. Jarvik, L. F. and Milne, J. F. Gerovital-H3: A review of the literature. In: Aging Vol. 2, Genesis and treatment of psychologic disorders in the elderly, (edited by Gershon, S. and Raskin, A.), pp. 203–227, Raven Press, New York, 1975.Google Scholar
  11. Jayne, H. W., Scheinberg, P., Rich, M. and Belle, M. S. The effects of intravenous papaverine hydrochloride on the cerebral circulation. J. Clin. Invest., 31:111–114, 1952.PubMedCrossRefGoogle Scholar
  12. Judge, T. G. and Urquihart, A. Naftidrofuryl — A double blind crossover study in the elderly. Curr. Med. Res. Opinion, 1:166–172, 1972.CrossRefGoogle Scholar
  13. Obrist, W. D. Cerebral physiology of the aged. Influence of circulatory disorders. In: Aging and the Brain, (edited by Charles M. Gaitz), pp. 117–133, Plenum Press, New York, 1972.CrossRefGoogle Scholar
  14. Prien, R. F. Chemotherapy in chronic organic brain syndrome. A review of the literature. Psychopharmacology Bulletin, 9:5–20, 1973.PubMedGoogle Scholar
  15. Roubicek, J., Geiger, C. H. and Abt, K. An ergot alkaloid preparation (hydergine) in geriatric therapy. J. Am. Geriatric Soc., 20: 222–229, 1972.Google Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Roland Branconnier
    • 1
  • Jonathan O. Cole
    • 1
  1. 1.Boston State HospitalBostonUSA

Personalised recommendations